The Maine Venture Fund is a professionally-managed venture capital fund that invests exclusively in Maine companies who demonstrate a potential for high growth and public benefit. The Fund has been actively investing in Maine companies since 1997, after its creation by an act of the Maine Legislature in 1995 to provide Maine companies and entrepreneurs access to patient sources of venture capital. The fund has received $13 million in capital contributions from the State of Maine and operates as a revolving “evergreen” fund.  The Maine Venture Fund specializes in small and medium Maine businesses and considers companies in nearly any industry that can demonstrate the potential for high growth and public benefit. The mission of the fund is to provide resources to attract, support, and help develop eligible small businesses with the potential for substantial growth and success that will contribute to the prosperity of Maine.

Maine Venture Fund

Advantage Capital has invested over $3.8 billion in more than 800 portfolio companies and projects nationwide since 1992. The firm specializes in growth equity, lending, and mezzanine debt capital investments spanning three distinct but complementary themes, driving local economic development and lasting impact in underserved communities. ____________________ Growing Small Business // 800+ PORTFOLIO COMPANIES // 34 STATES // 66,000+ JOBS SUPPORTED // Small businesses and the entrepreneurs who power them are fundamental to the U.S. economy, driving inclusive economic expansion that allows people and communities to thrive. Advantage Capital offers debt and equity investment opportunities and can provide senior, unitranche and subordinated debt, as well as minority equity financing. The firm invests in companies from a diverse array of industry sectors, including manufacturing, technology and business services, among others. It seeks to make an initial investment between $500K and $10M in companies with $1M+ EBITDA. Financing Affordable Homes // 89 PROJECTS SINCE 2015 // 8,000+ FAMILIES & SENIORS HOUSED // 7 STATES // Creating stronger communities goes beyond business investment and jobs. Financing housing in these same communities creates even more positive and lasting impacts. Expanding Renewable Energy Solutions // $130M IN CAPITAL DEPLOYED // 65 PROJECTS // 20,000+ HOMES POWERED // Increased access to renewable energy supports local green jobs and economic development while building the framework for tomorrow's carbon-free America. ____________________ Geographic Focus: Advantage Capital is committed to impact nationwide, with current emphasis in the following states: Alabama, Arkansas, Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky, Louisiana, Michigan, Mississippi, Missouri, Nebraska, Nevada, New Mexico, Ohio, Pennsylvania, Tennessee, Texas, Utah, Virginia, West Virginia ____________________ Advantage Capital is headquartered in New Orleans, Louisiana and has offices in the following locations: St. Louis, MO; New York, NY; Austin, TX; Hanover, NH; Washington, D.C.; Napa, CA; Nevada.

Advantage Capital

Morningside Venture Investments is an investment group that provides industry investments and social responsibility. It was founded in 1986 and is based in Shanghai, China.

Morningside Venture Investments

Werth Ventures is an angel investor for startup companies in the pharmaceutical, veterinary, and medical device field. Their group has successfully helped develop a TrkA specific inhibitor for treating pain; a first-line treatment for gastroparesis; a generic company specializing in injectable products; and a veterinarian company specializing in medicines for small companion animals. They are presently funding projects focused on developing cancer treatment drugs; using molecules to treat cardiovascular problems; and developing topical drugs to treat pain. Point-of-care test kits to detect concussions within 15 – 30 minutes of the event, innovative autoinjector technology using compressed gas, and a special imaging of the brain to detect brain damage related to Alzheimer's and CTE are also efforts supported by Their funding. All three of these developments, when successfully approved, will be significant medical advances.

Werth Ventures

Bose Ventures is looking for startups that are pushing the envelope of AR to help build some of these new experiences. They are investing in startups that are developing apps, services, and technology that leverage and extend the Bose AR platform. If you are one of these innovative startups

Bose Ventures

Global Brain Corporation is a venture capital firm that invests in companies from seed or early to pre-IPO startups.  Global Brain has invested in 300+ startups from seed/early to pre-IPO startups and achieved 25 IPOs and 61 M&As as a result of providing hands-on support services and resources to its portfolio startups. Global Brain has managed a pure investment fund as well as multiple corporate venture capital funds partnered together with tier 1 public companies of telecom, real estate development, financial service, beverages, agriculture food, logistics, and electronic devices.

Global Brain Corporation

Medrhythms

Medrhythms is a digital therapeutics company that utilizes sensors, music, and software to develop evidence-based, neurologic interventions to measure and improve walking. The company was founded in 2013 and is headquartered in Boston, Massachusetts.

MedRhythms was founded by a neurologic music fellow at Spaulding Rehabilitation Hospital to improve walking, mobility, and related functional outcomes. The company uses a combination of sensors, music, and AI-powered software to provide rhythmic auditory stimulation that targets nerve cells that control movement to improve a patient’s walking functionalities.

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

MedRhythms

MedRhythms Announces Key Publications Confirming Efficacy, Safety, and Usability of InTandem™ for Chronic Stroke ...

<div>
 
 Founded in 2016 by a neurologic music fellow at Spaulding Rehabilitation Hospital, MedRhythms uses a combination of sensors, music, and AI-powered software to provide rhythmic auditory stimulation that targets nerve cells that control movement to improve a patient&rsquo;s walking functionalities. In 2020, the company's DTx product received the Breakthrough Device designation from the US Food &amp; Drug Administration (FDA) aimed at chronic walking deficits caused by a stroke. It plans to expand its pipeline to include other neurological conditions in the long-term including Parkinson&rsquo;s, acute stroke, and multiple sclerosis.&nbsp;
 
 
 The company is preparing to begin clinical trials in order to obtain approval from the FDA for commercialization. In May 2022, 
 MedRhythms ​​signed a licensing agreement with multinational biotech company Biogen to develop and commercialize its MR-004 product to improve mobility for individuals diagnosed with multiple sclerosis (MS).&nbsp;Its MR-004 therapeutic was developed to treat gait deficits and mobility problems caused by MS.&nbsp;Under the terms of the agreement, MedRhythms would receive an upfront payment of USD 3 million from Biogen and a further USD 117.5 million based on certain development and commercial milestones. The former is also entitled to tiered royalties based on sales.&nbsp;
 
 
 
</div>

MedRhythms was founded by a neurologic music fellow at Spaulding Rehabilitation Hospital to improve walking, mobility, and related functional outcomes. The company uses a combination of sensors, music, and AI-powered software to provide rhythmic auditory stimulation that targets nerve cells that control movement to improve a patient’s walking functionalities.The company's flagship product, InTandem (MR-001), is an FDA-approved neurorehabilitation system that aims to improve walking and ambulation in adults with chronic stroke walking deficits. The system showed improvement in gait speed during its pivotal trial. Additionally, MedRhythms has a pipeline targeting gait deficits in multiple sclerosis (MS), Parkinson's disease, post-acute stroke, functional neurological disorder, aging in place, and cognition.Key customers and partnershipsIn May 2022, the company entered a license agreement with Biogen, worth up to USD 120 million, for MR-004, an investigational digital therapeutic targeting gait deficits in MS. Furthermore, in September 2021, MedRhythms partnered with Universal Music Group, granting access to its extensive music library for therapeutic use.

Cardiomo Care is developing noninvasive wearable devices to alert users and caretakers when there are abnormalities in the heartbeat. The company’s AI engine, trained on existing and growing data sets, can predict potential heart issues up to two hours before they occur, enabling early detection and intervention for arrhythmias and other cardiovascular diseases (CVDs).The company's product, CardiomoPatch, is a waterproof, wearable patch capable of long-term wear with a 10-day battery life. The patch monitors a patient's cardiac data, including ECG outputs, breathing, and skin temperature, and transmits the data via a mobile app for analysis by Cardiomo's AI engine.&nbsp;As of May 2024, the company is yet to commercialize its product and has over 1,600 pre-orders.

Cardiomo Care

Omada is a prevention-focused digital therapeutics startup that helps members achieve health goals through lifestyle changes. It offers four evidence-based, virtual prevention programs for managing hypertension, musculoskeletal (MSK) issues, prediabetes, and diabetes.Omada offers real-time data tracking through connected devices (such as wireless scales, blood pressure, and glucose monitors) and access to personalized coaching sessions via a mobile app as part of its prevention program. It also provides an online community of peers with similar health conditions to discuss challenges and provide support. In May 2021, Omada became the first fully-virtual healthcare provider to earn the National Committee for Quality Assurance’s Population Health Program Accreditation for its type 2 diabetes and type 2 diabetes + hypertension programs.Unlike its peers, Omada operates a performance-based business model where it charges clients an enrollment fee based on the number of users and a performance fee based on how much weight their employees lose. In May 2020, the company acquired virtual physical therapy startup Physera.Key customers and partnershipsAs of May 2024, Omada had more than 1 million members from more than 1,900 enterprise clients across all 50 US states. Its B2B employer and health plan client base include key clients such as American Eagle, Kaiser Permanente, Costco Wholesale, 3M, and Marvin. Additionally, the company has partnered with health systems and hospitals such as Intermountain Healthcare to provide its preventive programs as a covered benefit.In <a href="https://sp-edge.com/updates/15587">January 2023</a>, the company partnered with health service company Castell (a subsidiary of Intermountain Healthcare) to provide its diabetes programs to members from Intermountain Healthcare’s primary care providers in its Utah Medical Group. Further in <a href="https://sp-edge.com/updates/25245">January 2024</a>, the company partnered with Amazon to expand access to its cardiometabolic program.

Omada Health

VillageMD provides primary care services for patients. It also provides tools, technology, and staffing support needed for physicians to deliver high-quality services. VillageMD’s service delivery methods include traditional freestanding clinics, Village Medical at Walgreens co-located clinics, as well as at-home and around-the-clock virtual visits. It also leverages a team-based approach to care where physicians lead nurse practitioners, pharmacists, mental health specialists, and dietitians to offer a holistic care program. The technology of VillageMD includes docOS, an operating system that enables better patient care by connecting various clinical source systems with ongoing patient-generated data coupled with an AI engine to continuously analyze messages to enable patient self-care.The company made several acquisitions to expand its footprint: 1) <a href="https://sp-edge.com/updates/14347">Summit Health</a> for USD 8.9 billion in November 2022, 2) Healthy Interactions, an interactive patient education platform, in February 2022, and 3) <a href="https://sp-edge.com/updates/16968">Starling Physicians</a>, a primary care and specialty care provider, in March 2023.Key customers and partnershipsIn June 2020, VillageMD and Walgreens Boots Alliance announced a collaborative effort to open at least 600 Village Medical centers at Walgreens across more than 30 US markets by 2025. Walgreens invested USD 5.2 billion in VillageMD (from the previously announced USD 1.0 billion), raising its ownership stake to 63% (from 30%).However, as of May 2024, Walgreens had plans to close 160 VillageMD clinics as part of a cost-cutting plan.

VillageMD

Cityblock Health is a value-based healthcare provider focused on delivering comprehensive care to underserved communities, primarily Medicaid and lower-income Medicare beneficiaries. The company combines primary care, behavioral health, and social services to address the complex physical, mental, and social needs of its members.Cityblock's model involves partnering with local community-based organizations and deploying multidisciplinary care teams that include doctors, nurses, behavioral health specialists, and community health workers. These teams provide personalized care through 24/7 access to multi-modal care delivery, including in-home visits, telehealth, and community health hubs.The services of Cityblock are available to members at no additional cost if they are covered by an eligible health plan.Key Customers and PartnershipsAs of May 2024, the company’s services were available in seven states across the US and served over 100,000 members.In May 2024, it partnered with <a href="https://sp-edge.com/updates/29647">Sunshine Health</a> to expand to Florida, and, in <a href="https://sp-edge.com/updates/13270">September 2022</a>, it partnered with MDwise to expand into Indiana. Prior to that, the company had partnered with insurance providers such as ConnectiCare (Connecticut), Tufts Health Plan (Massachusetts), Emblem Health (New York), Healthy Blue (North Carolina), Molina Healthcare (Ohio) and CareFirst (Washington DC).Funding and FinancialsCityblock is a spin-off of Sidewalk Labs, an Alphabet company that incubates and invests in tech companies and products to improve urban infrastructure. It completed a USD 400 million Series D funding round led by Softbank in <a href="https://sp-edge.com/updates/5326">September 2021</a>, valuing the company at USD 5.7 billion. The funds were used to expand its services.

Cityblock Health

Everside Health (formerly Paladina Health) offers preventative care for chronic conditions and primary, mental and occupational healthcare treatments for acute conditions. Patients benefit from around-the-clock access to care, same-day or next-day appointments for in-person, and virtual care visits with zero copays.Everside aims to generate around 17% healthcare cost savings in three years and 31% in five years for its corporate members by leveraging a data-driven approach to care coordination.The company leverages data from past medical records, predictive analytics, and AI in the delivery of preventative care services.Founded in 2010 under the name Paladina Health, the company was rebranded in November 2020 as Everside Health following a merger between three primary care groups (Paladina, Activate Healthcare, and Healthstat). Furthermore, in February 2024, Everside Health merged with primary care provider Marathon Health to form a combined entity that would operate as Marathon Health, and, as of May 2024, the integration was ongoing.Key customers and partnershipPost-merger with Marathon Health, the combined entity would serve 2.5 million patients through over 680 clinics across 41 states.Funding and financialsThe company received its most recent investment in July 2022, amounting to USD 164 million in growth equity funding. The round was led by New Enterprise Associates (NEA). The funds were allocated toward growing its market presence and exploring opportunities for M&amp;A as well as to enhance and improve its product features. Additionally, the firm planned to expand its coverage of specialty care services aimed at individuals, employers, and union organizations.

Everside Health

Platforms offer a subscription-based or B2B-sponsored, evidence-based program for managing a specific long-term health condition.

DPCs offer value-based primary and preventive care services addressing whole-person (social, mental, physical) needs for a fixed monthly or annual fee paid by either the patient, insurance provider, or employer.

Companies offer B2B and D2C evidence-based treatments delivered via software programs to prevent and manage a variety of chronic conditions.

Tools that collect and analyze real-time patient data that supports healthcare providers with clinical decisions,  improves patient outcomes, and reduces medical errors.

Companies offer independent physician practices and hospitals with the tools (patient engagement, care coordination, administrative services) to help manage and improve clinical health outcomes of a defined group of individuals or large populations.

Platforms are used to track and gather patient health-related information via either a connected device or at-home test kits to detect the early onset of disease and identify any abnormalities in readings—but do not include a treatment plan.

To gather large amounts of real-time data for chronic care management, DTx, and patient monitoring

XR used by some startups for chronic pain management

Offers digital means of providing direct primary care, passive remote monitoring, chronic care management, etc.

AI/ML is used in predictive analytics, diagnostics tools, and population management

Offers tailored preventive interventions and treatments to the specific needs and characteristics of each individual

MedRhythms

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless